Reversible Dysgeusia Attributed to Losartan
1998; American College of Physicians; Volume: 129; Issue: 1 Linguagem: Inglês
10.7326/0003-4819-129-1-199807010-00023
ISSN1539-3704
Autores Tópico(s)Receptor Mechanisms and Signaling
ResumoLetters1 July 1998Reversible Dysgeusia Attributed to LosartanMarten Heeringa, MSc and Eugene P. van Puijenbroek, MDMarten Heeringa, MScNetherlands Pharmacovigilance Foundation LAREB; Hertogenbosch, the NetherlandsSearch for more papers by this author and Eugene P. van Puijenbroek, MDNetherlands Pharmacovigilance Foundation LAREB; Hertogenbosch, the NetherlandsSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-129-1-199807010-00023 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Like angiotensin-converting enzyme (ACE) inhibitors, losartan interferes with the renin-angiotensin-aldosterone system by decreasing angiotensin II-mediated effects. Although losartan and ACE inhibitors have similar therapeutic potency, losartan reportedly has fewer adverse effects because of selective antagonism of angiotensin I receptors [1]. Schlienger and colleagues [2] recently described a patient in whom losartan induced reversible ageusia; we present two similar reports.A 49-year-old woman had been using enalapril (10 mg/d) for the treatment of hypertension. Because of fatigue, therapy was changed to losartan (50 mg/d). One week after the initiation of therapy, the patient reported a persistent metallic taste, ...References1. Tikkanen I, Omvik P, Jensen HA. Comparison of the angiotensin II antagonist losartan with the angiotensin coverting enzyme inhibitor enalapril in patients with essential hypertension. J Hypertens. 1995; 13:1343-51. Google Scholar2. Schlienger RG, Saxer MS, Haefeli WE. Reversible ageusia associated with losartan. Lancet. 1996; 347:471-2. Google Scholar3. Stroeder D, Zeissig I, Heath R. Angiotensin-II-antagonist cGP 48933 (Valsartan). Ergebnisse einer doppelblinden, plazebo-kontrolierten Multicenter-Studie. Nieren und Hochdruckkrankheiten. 1994; 23:217-20. Google Scholar4. Henkin RI. Drug-induced taste and smell disorders. Drug Safety. 1994; 11:318-77. Google Scholar Author, Article, and Disclosure InformationAffiliations: Netherlands Pharmacovigilance Foundation LAREB; Hertogenbosch, the Netherlands PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByDrug-Induced Taste DisordersNeurological complications of cardiovascular drugsMedications and Oral Health: Points to Consider in Older PeopleAntiarrhythmic drug-induced smell and taste disturbancesPart 3: Impact of systemic conditions and medications on oral healthLosartanCardiovascular drugs-induced oral toxicities: A murky area to be revisited and illuminatedCardiovascular DrugsDrug-induced taste disordersDrugs Used to Treat Hypertension, Heart Failure, and Angina PectorisLosartanComparative Study of Taste Disturbance by Losartan and Perindopril in Healthy VolunteersAngiotensin II receptor blocker-induces blunted taste sensitivity: comparison of candesartan and valsartanClinical Pharmacokinetics of LosartanEffects of drugs on olfaction and tasteSubclinical alteration of taste sensitivity induced by candesartan in healthy subjectsCardiovascular DrugsInfluences of antihypertensive and antihyperlipidemic drugs on the senses of taste and smellIdiopathic dysgeusia; an open trial of alpha lipoic acid (ALA) therapyReversible ageusia induced by losartan: a case reportMedication‐Induced Taste DisturbancesAntihypertensive drugsAngiotensin II Receptor Antagonists and HypertensionLosartan potassium 1 July 1998Volume 129, Issue 1Page: 72KeywordsACE inhibitorsAngiotensin converting enzymeCalciumEmotionsFatigueHypertensionSafetyTasteTongueZinc Issue Published: 1 July 1998 CopyrightCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Referência(s)